Physician profile
Eric Ofori
NPI 1104057751
$2,750.80
in general payments reported to CMS, 2019-2025
20 companies · $307 in 2025
The $307 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $127 · 2021: $189 · 2022: $669 · 2023: $243 · 2024: $663 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,173 · Education: $39.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,173.21 |
| Education | $39.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $560.12 | 2019-2024 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $425.29 | 2020-2025 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $344.26 | 2020-2024 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $342.25 | 2019-2025 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $260.44 | 2019-2024 | Jynarque |
| Alexion Pharmaceuticals, INC. | $202.19 | 2019-2024 | Ultomiris |
| Fresenius USA Marketing, INC. | $81.48 | 2022-2024 | Velphoro |
| Ardelyx, INC. | $76.21 | 2024-2025 | Ibsrela |
| Horizon Therapeutics Plc | $71.79 | 2019-2022 | |
| Amgen INC. | $66.87 | 2022-2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $63.63 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.79 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $41.07 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $37.73 | 2024-2025 | Tarpeyo |
| Genzyme Corporation | $37.41 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amicus Therapeutics, INC. | $31.80 | 2022 | |
| Mallinckrodt Enterprises LLC | $22.87 | 2019 | |
| Lilly USA, LLC | $21.17 | 2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12.35 | 2019 | |
| Travere Therapeutics, INC. | $3.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Ofori listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.